Is class I recommendation for aspirin use in CVD prevention too strong?

Is class I recommendation for aspirin use in CVD prevention too strong
5' education - Oct. 12, 2022 - Prof. John Cleland, MD, PhD
  • Overview

    CSI Barcelona In response to the Grand Debate "Time to say goodbye to aspirin in CVD prevention?" at the ESC 2022, Katrien Castelijns asks Prof. Cleland about his view on this topic.

  • Educational information

    In the Cardiovascular Scene Investigation (CSI) series, investigators from Utrecht, the Netherlands report at the ESC congress, from the perspective of young investigators. They interview researchers/presenters about study results.

  • Faculty

    Prof. John Cleland, MD, PhD is a cardiologist and director of the Robertson Centre for Biostatistics & Clinical Trials at the University of Glasgow and Professor of Clinical Cardiology at Imperial College London.

    The interviewer is Katrien Castelijns, MD, PhD candidate at the department of Vascular Medicine at the UMC Utrecht in the Netherlands.

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free